Hashimoto’s Thyroiditis – Market Insights, Epidemiology, and Market Forecast – 2036, provides a comprehensive assessment of the Hashimoto’s Thyroiditis market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates historical and forecasted epidemiology, patient burden, diagnosis and treatment patterns, market dynamics, emerging therapies, competitive intelligence, drug uptake, reimbursement, pricing, and unmet medical needs through 2036.
(Albany, New York) – 22nd Sep 2026 – DelveInsight’s latest report, “Hashimoto’s Thyroiditis – Market Insights, Epidemiology, and Market Forecast – 2036,” provides a comprehensive assessment of the Hashimoto’s Thyroiditis market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates historical and forecasted epidemiology, patient burden, diagnosis and treatment patterns, market dynamics, emerging therapies, competitive intelligence, drug uptake, reimbursement, pricing, and unmet medical needs through 2036.
According to DelveInsight, the Hashimoto’s Thyroiditis market across the 7MM was approximately USD 2 billion in 2025 and is projected to expand at a 2.7% CAGR during 2026–2036. The United States represented the largest market, with a market size of more than USD 1 billion in 2025, while the EU4 and the UK together accounted for nearly USD 600 million, and Japan represented more than USD 100 million.
Key Takeaways from the Hashimoto’s Thyroiditis Market
Keen to know more about the Hashimoto’s Thyroiditis market? Request a sample copy of the report for detailed market insights, epidemiology, treatment patterns, competitive intelligence, and forecast analysis. https://www.delveinsight.com/sample-request/hashimotos-thyroiditis-market
Key Factors Driving the Hashimoto’s Thyroiditis Market
Rising Patient Burden
The growing prevalence and diagnosis of Hashimoto’s Thyroiditis are contributing to an expanding patient population requiring long-term monitoring and thyroid hormone replacement. DelveInsight estimates approximately 20 million diagnosed prevalent cases across the 7MM in 2025, with the burden expected to increase during the forecast period.
The disease represents one of the leading causes of hypothyroidism, creating sustained demand for diagnosis, disease monitoring, and hormone replacement therapy.
High Female Disease Burden
Hashimoto’s Thyroiditis disproportionately affects women. In the US, approximately 9 million female diagnosed cases were reported in 2025 compared with around 2 million male cases. The report attributes this female predominance to factors including estrogen-mediated immunomodulatory effects and X-linked genetic factors that can increase susceptibility to autoimmune thyroid disorders.
Growing Recognition and Diagnosis
Diagnosis incorporates clinical symptoms, serological testing, and imaging. Anti-thyroid peroxidase antibodies are an important diagnostic marker, while thyroid ultrasound can reveal characteristic heterogeneous and hypoechoic changes.
Improved awareness and diagnostic evaluation can contribute to identification of previously undiagnosed patients, expanding the addressable population for disease management.
Significant Unmet Need for Disease-modifying Therapies
Current management primarily corrects thyroid hormone deficiency rather than directly addressing the underlying autoimmune process. The absence of approved immunomodulatory or disease-modifying therapies represents a major gap in the treatment landscape.
Consequently, therapies capable of reducing autoimmune-mediated thyroid damage while preserving thyroid function could introduce a new treatment paradigm.
Emergence of Targeted Small-molecule Therapy
The development of Isomyosamine (MYMD-1) represents an emerging approach focused on inflammatory pathways involved in autoimmune disease. The oral therapy is designed to selectively inhibit TNF-α when it becomes overactivated and may offer an alternative to conventional injectable or infusion-based immune therapies.
Competitive Landscape
The Hashimoto’s Thyroiditis treatment landscape remains relatively limited because no disease-modifying therapy has received approval specifically for the underlying autoimmune pathology.
The key company identified in the emerging pipeline is:
The key emerging therapy is:
Isomyosamine is an orally administered small molecule being investigated for Hashimoto’s Thyroiditis. According to DelveInsight, TNF Pharmaceuticals had an active IND for a Phase II clinical trial as of August 2024; however, as of early 2026, there was no clear public confirmation that the Phase II trial had begun.
The current treatment landscape remains dominated by thyroid hormone replacement, particularly levothyroxine.
Recent Developments in the Hashimoto’s Thyroiditis Market
What is Hashimoto’s Thyroiditis?
Hashimoto’s Thyroiditis, also known as chronic lymphocytic thyroiditis or autoimmune thyroiditis, is an autoimmune disorder characterized by immune-mediated destruction of thyroid tissue. The disease involves lymphocytic infiltration of the thyroid gland and the development of autoantibodies targeting thyroid antigens.
Hashimoto’s Thyroiditis is a leading cause of hypothyroidism. As thyroid tissue is progressively damaged, patients can develop insufficient thyroid hormone production and symptoms associated with hypothyroidism.
The disease is diagnosed through a combination of clinical evaluation, thyroid function testing, serological markers, and imaging. Anti-thyroid peroxidase antibodies are an important marker, while ultrasound may demonstrate a heterogeneous and hypoechoic thyroid with characteristic micronodules. In selected cases, cytological or histopathological evaluation may be performed to confirm the diagnosis or exclude malignancy.
Current Treatment Landscape
There is currently no approved disease-modifying therapy specifically for Hashimoto’s Thyroiditis. Treatment primarily focuses on correcting the hypothyroidism caused by autoimmune thyroid destruction.
Levothyroxine
Levothyroxine (LT4) remains the standard treatment for overt hypothyroidism associated with Hashimoto’s Thyroiditis. DelveInsight notes a typical weight-based dosage of approximately 1.6–1.8 µg/kg per day, with therapy adjusted to normalize thyroid-stimulating hormone levels.
LT4 restores circulating thyroid hormone levels and helps alleviate systemic and cognitive symptoms associated with hypothyroidism.
Liothyronine
Liothyronine (T3) may occasionally be prescribed for individuals who continue to experience symptoms despite LT4 therapy. However, its use is more limited than levothyroxine.
Desiccated Thyroid Extract
Desiccated thyroid extract contains both T4 and T3 and is derived from animal thyroid tissue. It is less commonly used because of variability in hormone concentrations.
Combination T4 + T3 Therapy
Combination therapy using levothyroxine and liothyronine may be considered for selected patients. Treatment decisions depend on individual clinical circumstances and response to conventional hormone replacement.
Emerging Therapy: Isomyosamine (MYMD-1)
Isomyosamine (MYMD-1) is an oral small molecule being developed by TNF Pharmaceuticals for Hashimoto’s Thyroiditis. It is designed to selectively inhibit TNF-α, a cytokine involved in chronic inflammation and autoimmune disease.
Unlike conventional TNF-α inhibitors that broadly suppress immune activity, MYMD-1 is intended to selectively inhibit TNF-α when it becomes overactivated while preserving its physiological role in immune defense. Preclinical and clinical research has investigated its ability to regulate immune responses, including suppression of Th1-mediated inflammation and TNF-α release.
According to the report, MYMD-1 has a projected US launch year of 2031, although this remains provisional and may change depending on clinical and regulatory developments.
Hashimoto’s Thyroiditis Epidemiology
DelveInsight’s epidemiological analysis covers prevalent and diagnosed prevalent Hashimoto’s Thyroiditis cases across the 7MM, with further segmentation by gender, age, and cytology.
Key epidemiological findings include:
Epidemiology Segmentation
DelveInsight segments Hashimoto’s Thyroiditis epidemiology into:
Unmet Needs in Hashimoto’s Thyroiditis
Despite the availability of effective hormone replacement, several unmet needs remain:
The development of immunomodulatory therapies such as MYMD-1 could potentially expand treatment beyond hormone replacement and address the underlying inflammatory mechanisms of disease.
Scope of the Hashimoto’s Thyroiditis Market Report
To Know More About the Hashimoto’s Thyroiditis Market Report
Hashimoto’s Thyroiditis – Market Insights, Epidemiology, and Market Forecast – 2036
Table of Contents
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
